CCA
VRTX icon

Canyon Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Canyon Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-494,194
Closed -$36.4M – 55
2016
Q4 		$36.4M Sell
494,194
-209
-0% -$17K 1.22% 19
2016
Q3 		$43.1M Buy
494,403
+109,018
+28% +$10.3M 1.58% 14
2016
Q2 		$33.2M Sell
385,385
-2,283
-0.6% -$197K 1.32% 16
2016
Q1 		$30.8M Sell
387,668
-20,113
-5% -$1.82M 1.23% 22
2015
Q4 		$51.3M Sell
407,781
-323
-0.1% -$39K 1.58% 21
2015
Q3 		$42.5M Buy
408,104
+40,981
+11% +$5.26M 1.17% 26
2015
Q2 		$45.3M Buy
+367,123
New +$46.3M 1.2% 26

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return